Pegipanermin

培吉奈明

Report date: 2026/05/18 20:02:07
First In Class

Base Information

Drug NamePegipanermin
Drug Alias NameLIVNateQuellorINB-03XENP-345XPro-1595 +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor inhibitors
TargetsTumor necrosis factor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionNeurocognitive Disorders +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor IncEmory University
China Registration ClassN/A

Develop Information

Active CompaniesInmune Bio Inc
Inactive CompaniesN/A
Active IndicationsCognitive DysfunctionNeurocognitive DisordersTauopathies +[9] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Mental DisordersNervous System Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG